228 patents
Page 6 of 12
Utility
Human cytomegalovirus vaccine
14 Dec 21
The disclosure relates to HCMV ribonucleic acid (RNA) vaccines, as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Shinu John
Filed: 1 May 20
Utility
Preparation of Lipid Nanoparticles and Methods of Administration Thereof
9 Dec 21
The present disclosure provides methods of producing lipid nanoparticle (LNP) formulations and the produced LNP formulations thereof.
Allen HORHOTA, Christopher Karl MCLAUGHLIN, Jessica CHENEY, Ben GELDHOF, Jeffrey HRKACH, Melissa J. MOORE, Stephen G. HOGE
Filed: 20 Sep 19
Utility
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
30 Nov 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua P. Frederick, Ailin Bai, Vladimir Presnyak, Stephen G. Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Filed: 16 Aug 19
Utility
Delivery of Dna
11 Nov 21
The compositions and methods described herein relate to lipid nanoparticle encapsulation of DNA sequences, including DNA vectors, for delivery into a human subject.
Stoil Dimitrov, Eric Huang
Filed: 21 May 19
Utility
Sterol Purification
11 Nov 21
The invention relates to sterol esters and methods for producing purified sterols that can be utilized in methods for producing a lipid nanoparticle.
Gabor BUTORA, Jin LIM, Gary SHEN, Alison VOLKERT
Filed: 19 Sep 19
Utility
Methods of Using OX40 Ligand Encoding Polynucleotides
14 Oct 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules comprising an mRNA encoding an OX40L polypeptide.
Joshua P. FREDERICK, Ailin BAI
Filed: 16 Mar 21
Utility
Modified Nucleosides, Nucleotides, and Nucleic Acids, and Uses Thereof
7 Oct 21
The present disclosure provides modified nucleosides, nucleotides, and nucleic acids, and methods of using them.
Antonin DE FOUGEROLLES, Atanu ROY
Filed: 25 Sep 20
Utility
Rna Polymerase Variants for Co-transcriptional Capping
7 Oct 21
The present disclosure provides RNA polymerase variants for high efficiency transcription.
Athanasios Dousis, Kanchana Ravichandran, Amy E. Rabideau, Margaret Franklin, Kevin Smith
Filed: 20 May 21
Utility
Polynucleotides Encoding INTERLEUKIN-12 (IL12) and Uses Thereof
30 Sep 21
The present disclosure relates to polynucleotides comprising an open reading frame of linked nucleosides encoding human interleukin-12 (IL12), functional fragments thereof, and fusion proteins comprising IL12.
Joshua FREDERICK, Susannah HEWITT, Ailin BAI, Stephen HOGE, Vladimir PRESNYAK, Iain MCFADYEN, Kerry BENENATO, Ellalahewage Sathyajith KUMARASINGHE
Filed: 5 May 21
Utility
Modified Polynucleotides for the Production of Biologics and Proteins Associated with Human Disease
30 Sep 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides, primary transcripts and mmRNA molecules.
Stephane BANCEL, Tirtha CHAKRABORTY, Antonin DE FOUGEROLLES, Sayda M. ELBASHIR, Matthias JOHN, Atanu ROY, Susan WHORISKEY, Kristy M. WOOD, Paul HATALA, Jason P. SCHRUM, Kenechi EJEBE, Jeff Lynn ELLSWORTH, Justin GUILD
Filed: 14 Sep 20
Utility
Personalized Cancer Vaccine Epitope Selection
2 Sep 21
The disclosure relates to optimized cancer vaccines, as well as methods of making the vaccines, using the vaccines, and compositions comprising the vaccines.
Shan Zhong, Benjamin Breton, Iain Mcfadyen, Kristen Hopson, Vincent Luczkow, Maija Garnaas
Filed: 27 Jun 19
Utility
Polynucleotides Encoding Immune Modulating Polypeptides
2 Sep 21
The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotide molecules encoding at least one polypeptide of interest to modulate the immune response.
Joseph Beene BOLEN, Joshua P. FREDERICK
Filed: 21 Sep 20
Utility
Polynucleotides Encoding GALACTOSE-1-PHOSPHATE Uridylyltransferase for the Treatment of Galactosemia Type 1
2 Sep 21
The invention relates to mRNA therapy for the treatment of galactosemia type 1 (Gal-1). mRNAs for use in the invention, when administered in vivo, encode human galactose-1-phosphate uridylyltransferase (GALT), isoforms thereof, functional fragments thereof, and fusion proteins comprising GALT. mRNAs of the invention are preferably encapsulated in lipid nanoparticles (LNPs) to effect efficient delivery to cells and/or tissues in subjects, when administered thereto. mRNA therapies of the invention increase and/or restore deficient levels of GALT expression and/or activity in subjects. mRNA therapies of the invention further decrease levels of toxic metabolites associated with deficient GALT activity in subjects, namely galactose-1-phosphate (Gal-1-P).
Paolo Martini, Stephen Hoge, Kerry Benenato, Vladimir Presnyak, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Ding An, Staci Sabnis
Filed: 21 Jan 21
Utility
Respiratory virus nucleic acid vaccines
31 Aug 21
Provided herein, in some embodiments, are vaccines (and vaccination methods) that include a ribonucleic acid (RNA) polynucleotide encoding a human metapneumovirus (hMPV) F protein and a RNA polynucleotide encoding a human parainfluenza virus 3 (hPrV3) F protein.
Giuseppe Ciaramella, Sunny Himansu
Filed: 8 Dec 17
Utility
Methods for Therapeutic Administration of Messenger Ribonucleic Acid Drugs
26 Aug 21
The disclosure features methods of reducing or inhibiting an anti-drug antibody response in a subject, as well as methods of reducing or inhibiting unwanted immune cell activation in a subject to be treated with a messenger RNA (mRNA), comprising administering to the subject a mRNA, e.g., a chemically modified messenger RNA (mmRNA), encoding a polypeptide of interest, wherein the mRNA comprises at least one microRNA (miR) binding site for a miR expressed in immune cells, such as miR-126 binding site and/or miR-142 binding site, such that an anti-drug antibody response to the polypeptide or interest, or unwanted immune cell activation (e.g., B cell activation, cytokine secretion), is reduced or inhibited in the subject.
Stephen HOGE, Tirtha CHAKRABORTY, Gilles BESIN, Ruchi JAIN
Filed: 29 Sep 20
Utility
Zoonotic Disease Rna Vaccines
19 Aug 21
The disclosure relates to Lassa virus, Nipah virus, and betacoronavirus ribonucleic acid vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Giuseppe Ciaramella, Sunny Himansu, Vladimir Presnyak, Kerry Benenato, Ellalahewage Sathyajith Kumarasinghe
Filed: 22 Jan 21
Utility
Engineered Nucleic Acids and Methods of Use Thereof
5 Aug 21
Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression.
Jason P. Schrum, Gregory J. Sieczkiewicz, Kenechi Ejebe, Sayda M. Elbashir
Filed: 16 Jul 20
Utility
Coronavirus Rna Vaccines
29 Jul 21
The disclosure relates to coronavirus ribonucleic acid (RNA) vaccines as well as methods of using the vaccines and compositions comprising the vaccines.
Mihir Metkar, Vladimir Presnyak, Guillaume Stewart-Jones
Filed: 21 Aug 20
Utility
Removal of Dna Fragments In Mrna Production Process
29 Jul 21
The present invention describes methods of removing DNA from an RNA transcript during the mRNA production process.
William Joseph ISSA, Yuxun WANG, Stephane BANCEL
Filed: 7 Dec 20
Utility
Combinations of mRNAs encoding immune modulating polypeptides and uses thereof
27 Jul 21
The disclosure relates to compositions and methods for the preparation, manufacture and therapeutic use of combinations of immunomodulatory polynucleotides (e.g., mRNAs) encoding an immune response primer polypeptide (e.g., an interleukin 23 (IL-23) polypeptide or an interleukin 36γ (IL-36-gamma) polypeptide), and an immune response co-stimulatory signal polypeptide (e.g., an OX40L polypeptide).
Joshua Frederick, Ailin Bai, Vladimir Presnyak, Stephen G. Hoge, Kerry Benenato, Iain McFadyen, Ellalahewage Sathyajith Kumarasinghe, Susannah Hewitt
Filed: 15 Oct 20